Support Centre
29 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
EndoVascular Aneurysm Repair (EVAR) Trials 1 and 2
DOI 10.1186/ISRCTN55703451
ClinicalTrials.gov identifier
EudraCT number
Public title EndoVascular Aneurysm Repair (EVAR) Trials 1 and 2
Scientific title EndoVascular Aneurysm Repair (EVAR) randomised controlled trial in patients with abdominal aortic aneurysm (EVAR 1 and 2)
Acronym EVAR
Serial number at source HTA 95/02/99; HTA 95/02/02
Study hypothesis Endovascular Aneurysm Repair (EVAR) to exclude Abdominal Aortic Aneurysm (AAA) was introduced in the early 1990ís for patients of poor health status considered unfit for major surgery. As the technology has progressed, EVAR has become an alternative choice of treatment for patients considered fit for open repair as it is minimally invasive and generally involves a shorter stay in hospital. The two EndoVascular Aneurysm Repair (EVAR) Trials were instigated to assess the safety and efficacy of endovascular aneurysm repair in the treatment of AAA in terms of mortality, quality of life, durability and cost-effectiveness for patients considered fit (EVAR Trial 1) or unfit (EVAR Trial 2) for open repair.

Please note that the scientific title has been added as of 03/02/2009.
Lay summary Not provided at time of registration
Ethics approval MREC North West, approved on 28/04/1998:
EVAR Trial 1, ref: 98/8/26
EVAR Trial 2, ref: 98/8/27
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Cardiovascular diseases: peripheral arterial disease
Participants - inclusion criteria EVAR Trial 1:
1. Males or females
2. Aged at least 60 years
3. Abdominal Aortic Aneurysm (AAA) measuring at least 5.5 cm on a Computed Tomography (CT) scan
4. AAA deemed anatomically suitable for an EndoVascular Aneurysm Repair (EVAR) device
5. Patient considered anaesthetically fit for an open repair

EVAR Trial 2:
1. Males or females
2. Aged at least 60 years
3. Abdominal Aortic Aneurysm (AAA) measuring at least 5.5 cm on a CT scan
4. AAA deemed anatomically suitable for an EndoVascular Aneurysm Repair (EVAR) device
5. Patient considered anaesthetically unfit for an open repair
Participants - exclusion criteria EVAR Trial 1:
Does not match inclusion criteria

EVAR Trial 2:
Patients with hostile abdomen anatomically unsuitable for open repair but anaesthetically well enough for the open operation were excluded.
Anticipated start date 01/07/1999
Anticipated end date 30/06/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants EVAR 1: 900; EVAR 2: 280 (total 1180)
Interventions EVAR Trial 1:
EVAR versus open repair in patients considered fit for open repair.

EVAR Trial 2:
EVAR and medical management versus medical management alone in patients considered unfit for open repair

Randomisation closed at the end of June 2005 by which time 1656 patients had been enrolled (1082 into EVAR Trial 1 and 404 into EVAR Trial 2). Follow-up continues until the end of 2009.
Primary outcome measure(s) All-cause and aneurysm-related mortality.

Added as of 06/02/2009:
Follow-up will be until the end of 2009.
Secondary outcome measure(s) 1. Health Related Quality of Life (HRQL):
1.1. SF-36® Health Survey at 1 year
1.2. Euroqol EQ-5D, assessed annually until the end of 2009
1.3. Patient Generated Index at 1 year
1.4. Stait-Trait Anxiety Index at 1 year
2. Durability of AAA grafts and incidence of complications and re-interventions, followed-up until the end of 2009
3. Costs and cost effectiveness. Data will be collected until the end of 2009.
4. Renal function, assessed annually until the end of 2009

Please note that methods of assessment for HRQL and the timepoints of assessment for all secondary outcome measures were added as of 06/02/2009.
Sources of funding NIHR Health Technology Assessment Programme - HTA (UK)
Trial website http://www.evartrials.org/
Publications 1. 2004 publication on trial design, methodology and progress in http://www.ncbi.nlm.nih.gov/pubmed/15015186
2. 2004 results on 30-day operative mortality in http://www.ncbi.nlm.nih.gov/pubmed/15351191
3. 2005 results of EVAR trial 1 in http://www.ncbi.nlm.nih.gov/pubmed/15978925
4. 2005 results of EVAR trial 2 in http://www.ncbi.nlm.nih.gov/pubmed/15978926
5. 2007 results on patient fitness and survival in http://www.ncbi.nlm.nih.gov/pubmed/17514695
6. 2007 device-specific results of secondary interventions and mortality in http://www.ncbi.nlm.nih.gov/pubmed/17572116
7. 2008 results on long-term cost-effectiveness in http://www.ncbi.nlm.nih.gov/pubmed/17876749
8. 2008 results on the rupture rate of large abdominal aortic aneurysms in http://www.ncbi.nlm.nih.gov/pubmed/18156938
9. 2010 results on rate of cardiovascular events in EVAR trial 2 in http://www.ncbi.nlm.nih.gov/pubmed/20096611
10. 2010 results on endovascular repair in patients physically ineligible for open repair in http://www.ncbi.nlm.nih.gov/pubmed/20382982
11. 2010 results on endovascular versus open repair in http://www.ncbi.nlm.nih.gov/pubmed/20382983
12. 2012 results on EVAR versus standard therapy in http://www.ncbi.nlm.nih.gov/pubmed/22381040
Contact name Prof  Roger  Greenhalgh
  Address Department of Surgery
Charing Cross Hospital
  City/town London
  Zip/Postcode W6 8RF
  Country United Kingdom
  Tel +44 (0)20 8846 7316
  Fax +44 (0)20 8846 7330
  Email r.greenhalgh@imperial.ac.uk
Sponsor Imperial College London (UK)
  Address South Kensington Campus
  City/town London
  Zip/Postcode SW7 2AZ
  Country United Kingdom
  Sponsor website: http://www3.imperial.ac.uk/
Date applied 25/04/2003
Last edited 05/04/2012
Date ISRCTN assigned 25/04/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.